Platelet-rich plasma has been used in hair medicine long enough now that the hype cycle has come and mostly gone. What's left is a legitimate but still-evolving evidence base, a treatment that works for many patients but not all, and a set of preparation variables that the field hasn't yet standardized. That's the honest situation, and it's actually a useful one for practitioners to understand clearly.
The 2025 literature brought some of the most comprehensive analyses to date. A meta-analysis pooling 43 randomized controlled trials and 1,877 participants confirmed that PRP consistently improves hair density compared to placebo. A parallel meta-analysis put PRP head-to-head against topical minoxidil across nine RCTs and found no significant difference in outcome. That's not bad news — it's useful clinical information. And a 2024 study measuring actual growth factor concentrations in patient-derived PRP samples gave us sharper insight into why some patients respond at 78% while others don't improve at all.
Here's a full breakdown of what the updated evidence actually says, what it doesn't, and what practitioners need to understand before recommending or supporting PRP in their client's care plan.
What PRP Is and Why It's Theoretically Relevant to Hair
Platelet-rich plasma is an autologous blood concentrate — meaning it's prepared from the patient's own blood. A blood draw is centrifuged to separate red blood cells from plasma, then centrifuged again (or not, depending on the protocol) to concentrate the platelet layer above the buffy coat. The result is a small volume of plasma with platelet concentrations typically three to six times higher than whole blood.
The clinical logic is based on what platelets do. When activated, platelets degranulate — they release the contents of their alpha granules, which include a suite of growth factors directly relevant to follicle biology: platelet-derived growth factor (PDGF), vascular endothelial growth factor (VEGF), transforming growth factor beta (TGF-β), insulin-like growth factor 1 (IGF-1), epidermal growth factor (EGF), fibroblast growth factor 2 (FGF-2), and others. These are not incidental compounds. They are the signaling molecules dermal papilla cells actually respond to during hair growth.
The theoretical case for PRP in hair loss is not superficial. The biology is real. The question the research has been working to answer is whether injecting concentrated growth factors into the scalp translates into clinically meaningful hair regrowth — reliably, across patients, at a level worth the cost and procedural burden.
The Mechanism: How PRP Targets the Follicle
Understanding why PRP was ever proposed for hair loss requires understanding the dermal papilla's role in controlling the hair cycle. The dermal papilla (DP) is a cluster of specialized mesenchymal cells at the base of the follicle that acts as the master regulator of hair growth. It receives signaling inputs from the surrounding microenvironment and, in turn, determines whether a follicle enters anagen, maintains it, or transitions into catagen. In androgenetic alopecia, DHT-driven suppression of DP cell activity progressively miniaturizes the follicle and shortens anagen duration. PRP's mechanism targets this at multiple levels.
The mechanism is genuinely multi-factorial, and that's part of what makes PRP both promising and difficult to study in isolation. You're not activating one pathway — you're simultaneously influencing angiogenesis, cell proliferation, apoptosis suppression, and stem cell signaling. The clinical effect, when it occurs, is likely the sum of all of these. Which also means that when it doesn't occur, the failure could be at any one of those points.
The 2025 Meta-Analysis: 43 Trials, 1,877 Patients
This is the most comprehensive meta-analysis on PRP and alopecia published to date. The researchers searched PubMed, EMBASE, and Scopus and identified 43 randomized controlled trials enrolling a total of 1,877 participants. The analysis covered multiple alopecia subtypes, primarily androgenetic alopecia but also alopecia areata and telogen effluvium.
The headline finding: PRP significantly improves hair density and reduces hair loss compared to placebo. This held across alopecia subtypes, though the effect was most consistently documented in AGA. The researchers also found that PRP improved patient satisfaction and clinical outcomes more broadly.
The more clinically actionable finding came in the subgroup analysis by preparation method. Activated PRP — where platelets are induced to release their growth factors via calcium chloride, calcium gluconate, or thrombin before injection — outperformed non-activated PRP in hair density outcomes and showed a lower frequency of adverse effects. Non-activated PRP was associated with more procedural side effects, and the effect size on hair density was smaller. This is not a minor methodological detail. It suggests that a meaningful share of the heterogeneity across PRP studies, and across clinical outcomes in practice, is driven by whether the platelets are actually releasing their growth factors before injection or relying on the in vivo environment to trigger degranulation.
Every meta-analysis on PRP runs into the same limitation: the studies pooled are measuring different things. Some use single-spin centrifugation, some double. Some activate with calcium, some don't activate at all. Some inject monthly, some every three weeks, some every six weeks. Some measure hair count, some measure hair density, some measure both. The result is a high-heterogeneity evidence base that makes definitive conclusions difficult. The 2025 meta-analysis acknowledged this clearly. "Moderate evidence" is the honest rating — not "proven" but meaningfully beyond placebo.
PRP vs. Minoxidil: What Head-to-Head Data Shows
This meta-analysis tackled the question practitioners actually ask: how does PRP compare to the standard-of-care options we already have? Across nine randomized controlled trials involving 451 participants with androgenetic alopecia, PRP and topical minoxidil showed no statistically significant difference in hair density outcomes.
That finding deserves careful interpretation. It does not mean PRP is equivalent to minoxidil in all relevant respects — cost, accessibility, frequency of use, patient experience, and mechanism of action are all very different. What it means is that in terms of measurable hair density change, the two treatments perform in a comparable range for AGA patients when PRP is administered correctly. For patients who don't tolerate minoxidil, or who want an autologous option with a different risk profile, PRP represents a legitimate alternative rather than an experimental reach.
An earlier 2024 systematic review in Skin Health and Disease (Oxford Academic) similarly concluded that PRP was comparable to minoxidil in efficacy for AGA, with the additional observation that patient satisfaction with PRP tended to be higher despite its more involved administration — which may reflect the therapeutic relationship built around the treatment as much as the biological outcome.
Who Responds — and Who Doesn't
This 2024 study is the most granular look at the PRP responder question published to date. The researchers did something most clinical PRP trials don't: they actually measured the growth factor concentrations in each individual patient's PRP sample before injecting it, then tracked clinical outcomes. Forty-six AGA patients were treated, and seven growth factors were quantified — EGF, FGF2, PDGF-BB, VEGF, GDNF, HGF, and TGF-β1.
PDGF-BB was consistently the highest-concentration growth factor across patients. The baseline hair density was 118.28 ± 26.10 hairs per cm². At final follow-up, it had increased to 133.30 ± 26.56 hairs per cm² — statistically significant (p < 0.001). Critically, 36 out of 46 patients (78.3%) showed measurable improvement. That means roughly 22% did not.
The non-responder question is one of the most important in the PRP literature and one of the least well answered. Based on the available evidence, several factors appear to predict lower response rates:
Most of the PRP literature and the clearest evidence applies to androgenetic alopecia. For alopecia areata, PRP is sometimes used adjunctively — typically alongside intralesional corticosteroids or as a standalone where steroids are not tolerated. The 2023 Cruciani meta-analysis (27 controlled trials, 1,117 subjects) included nine AA-specific trials and found some benefit, but the evidence quality was lower and the AA sample sizes smaller. PRP for AA should be understood as an adjunctive option with limited high-quality evidence, not a comparable intervention to what exists for AGA. Immunologically, AA and AGA are completely different conditions, and growth factor signaling through the Wnt pathway doesn't address the immune privilege collapse driving AA in the same direct way it addresses DP cell suppression in AGA.
The Preparation Question: Why Protocol Matters as Much as Treatment
The single most important variable the PRP literature has identified is one that practitioners have control over: preparation protocol. And yet it's the variable most inconsistently handled, both in research and in clinical practice.
The key decision points in PRP preparation are centrifugation (single spin versus double spin), the final platelet concentration target (typically 3–6× whole blood baseline), and whether to activate the platelets before injection. A 2024 randomized trial comparing single-spin versus double-spin centrifugation found that double-spin produced higher platelet concentrations, but clinical hair density improvement did not differ substantially between the two methods — suggesting that concentration above a threshold doesn't linearly improve outcomes. What matters is reaching that threshold and ensuring platelets are actually releasing their growth factors.
Activation typically uses calcium chloride or calcium gluconate added to the PRP immediately before injection. This triggers platelet degranulation, releasing the growth factor payload into the tissue rather than depending on the injection environment to do so. The 2025 meta-analysis found that activated PRP produced better hair density outcomes and fewer adverse effects than non-activated PRP. If you're supporting clients through a PRP regimen, asking whether their provider uses activated PRP is a clinically relevant question — not a niche one.
The injection depth and distribution pattern also matter. Intradermal injection at the level of the bulge and dermal papilla is the anatomical target. Too superficial and the growth factors don't reach the DP. Too deep and they're delivered into subcutaneous fat, where there's nothing relevant to stimulate. This is a technical skill that varies by practitioner, which is part of why PRP outcomes vary even when the same product protocol is used.
Female Hair Loss: A Different Profile of Evidence
A 2024 systematic review specifically examined the evidence for PRP in female hair loss across 21 studies published between 2015 and 2023, spanning female AGA, female pattern hair loss (FPHL), and chronic telogen effluvium (CTE). The review found positive outcomes across all three conditions, with PRP outperforming placebo on both hair density and patient-reported outcomes.
The authors noted that PRP's favorable safety profile and autologous nature make it a particularly useful option for female patients who want to avoid the systemic effects of minoxidil (such as unwanted facial hair) or who can't use finasteride. For CTE specifically, PRP may address the hair cycle disruption from below by providing the growth factor stimulus needed to restart follicles that have stalled in telogen — a mechanistically plausible action that aligns with what we know about IGF-1 and telogen exit signaling.
The 2025 Anitua meta-analysis also noted that the earlier subgroup analyses found stronger hair density effects in male-only trials compared to mixed-sex samples — suggesting that hormonal context and the specific mechanism of follicle suppression in female versus male AGA may modulate PRP response differently. This is an area where more sex-stratified data is needed.
What This Means for Trichologists
PRP sits squarely in the physician-supervised or physician-performed category. The injection protocol, preparation equipment, and clinical assessment required to do it properly are outside the scope of trichology practice. That's not a limitation unique to PRP — it applies to most procedural interventions in hair medicine. What it means in practice is that your role is as an informed educator and referral source, not an administrator of the treatment.
Understand what you're referring clients into. When a client tells you they're considering PRP or already doing it, you should be able to ask meaningful questions. Is the provider using activated PRP? What's the session frequency and maintenance plan? Are they tracking hair density with standardized photography or trichoscopy? These aren't gotcha questions — they're the difference between a protocol grounded in the evidence base and one that's performing the motions without the precision.
Set expectations accurately. PRP is not a cure. It does not reverse the androgenetic or immunological mechanisms driving hair loss. What it does, in good responders, is improve the follicular environment enough to support better cycling and measurable density increase. For most patients, that improvement requires maintenance — the follicle environment doesn't stay improved indefinitely after injections stop. Clients who understand this going in are clients who don't feel deceived when they need a top-up session at six months.
Know the non-responder population. Approximately 20–25% of patients in the clinical literature do not respond meaningfully to PRP. The strongest predictors of non-response are advanced disease stage with perifollicular fibrosis, poor PRP preparation, and inadequate session frequency. If a client has been through three or four properly administered PRP sessions with an experienced provider and is seeing no change, that is not a failure of effort — it's a clinical signal to reassess the diagnosis and mechanism.
Stay current on the combination therapy data. A growing body of work is examining PRP not as a standalone but as part of combination protocols — PRP plus topical minoxidil, PRP plus low-level laser therapy, PRP plus microneedling. The combination with microneedling in particular has generated positive case series data, with the hypothesis that microneedling-induced microchannels improve growth factor penetration into the dermal papilla zone. This is not yet supported by high-quality RCT data, but it's a direction worth following.
The Bottom Line
PRP for hair loss has graduated from experimental to evidence-supported — with important caveats. A 2025 meta-analysis of 43 RCTs confirmed that PRP consistently improves hair density over placebo, and a parallel meta-analysis found it comparable in efficacy to topical minoxidil for AGA. The mechanism is scientifically grounded: growth factors from activated platelets stimulate dermal papilla cell proliferation, promote angiogenesis via VEGF, counter DHT-mediated Wnt/β-catenin suppression, and extend anagen via anti-apoptotic signaling. Who responds best: patients with early-to-moderate AGA, properly prepared and activated PRP, adequate session frequency, and a provider with technical precision. Who doesn't respond well: patients with advanced fibrosis, non-activated preparations, inadequate platelet concentration, or insufficient treatment intervals. The field still lacks a standardized protocol, and evidence quality remains moderate due to heterogeneity across trials. But PRP is a legitimate tool in the hair medicine toolkit — as long as practitioners understand what it can and cannot do.